Avience Biomedicals IPO Day 2: GMP ₹73 (+₹13)

Welcome back to our daily deep dive into the Avience Biomedicals SME IPO on the NSE! As we enter Day 2 of its subscription period, the excitement is palpable, but the subscription numbers are still, shall we say, waiting to ignite. Let’s break down what’s happening and what it means for potential investors. The IPO, which opened yesterday, June 18th, 2026, and is set to close on June 22nd, 2026, with an issue price of ₹196 per share, is currently at a curious juncture.

Subscription Status

As of the end of Day 1 and the early hours of Day 2, the subscription figures for Avience Biomedicals are showing 0x across all categories – Retail, NII (Non-Institutional Investors), and QIB (Qualified Institutional Buyers). This might seem alarming at first glance, but for SME IPOs, especially on their initial days, this isn’t entirely uncommon. It often takes a few days for the momentum to build. Many investors, particularly larger institutions and HNIs (High Net Worth Individuals), prefer to wait and observe the trend before committing their capital. The lot size is 600 shares, meaning a single retail application would require ₹117,600. The absence of any subscriptions so far doesn’t necessarily signal a lack of interest; it might just mean investors are playing a waiting game. We’ll be keeping a very close eye on this as Day 2 progresses. The bottom line is, it’s too early to draw firm conclusions from these numbers alone.

GMP Update

Now, let’s talk about the Grey Market Premium (GMP). This is where things get interesting and offer a more immediate pulse on market sentiment. Yesterday, the GMP for Avience Biomedicals was around ₹60. Today, it has seen a healthy jump to ₹73. That’s an increase of ₹13, which is quite encouraging. A rising GMP generally indicates increasing demand and positive anticipation for the listing. At an issue price of ₹196 and a current GMP of ₹73, the expected listing price is around ₹269 (₹196 + ₹73). This represents a healthy potential listing gain of over 37%. This upward trend in GMP is a positive signal and suggests that market participants are feeling optimistic about Avience Biomedicals’ prospects post-listing. This is a development we’ll be monitoring closely throughout the IPO period.

Should You Apply?

So, the million-dollar question: should you be applying for the Avience Biomedicals IPO? It’s a balanced view at this point. On one hand, the subscription numbers are yet to show any traction, which could concern risk-averse investors. However, the steadily increasing GMP is a strong positive indicator. It suggests that the market is valuing the company well above its issue price, even before significant subscription data is out. Remember, SME IPOs can be volatile, and thorough due diligence is always recommended. As per SEBI advisories, investors should always conduct their own research and consult with their financial advisors before making any investment decisions. The information provided here is for informational purposes only and not investment advice. The potential listing gains indicated by the GMP are attractive, but they are also speculative and can change. For more detailed information on Avience Biomedicals, you can View Full Avience Biomedicals IPO Details. We’ll be back tomorrow with the Day 3 update, and hopefully, some more substantial subscription figures!